Med Spa Valuation and M&A: What an Aesthetic Practice Is Worth in 2026

The medical aesthetics industry has undergone a dramatic transformation. What was once a highly fragmented market composed of independent, physician-owned clinics has become one of the most active targets for private equity (PE) consolidation. Driven by high margins, recurring service demand, cash-pay structures that avoid insurance billing, and strong demographic tailwinds, financial sponsors have poured billions of dollars into the space.

For medical spa owners, this institutional interest represents an unprecedented opportunity to monetize their businesses. However, many owners operate under fundamental misconceptions about how their practices are valued, what buyers look for during due diligence, and how M&A deal structures work.

A med spa is not valued simply as a multiple of its gross revenue, nor is it priced like a standard retail business. In medical aesthetics, valuation is a complex calculation of adjusted cash flow, operational transferability, clinical safety compliance, and regulatory structural defensibility.

This guide provides an in-depth analysis of medical spa valuation and M&A. We explain the difference between revenue and EBITDA; outline the size-tiered multiple ranges; analyze the key value drivers that premium buyers look for; address the critical CPOM (Corporate Practice of Medicine) and PC-MSO compliance requirements; detail modern PE deal structures; analyze recent transaction data; and explain how clinical safety protocols serve as a direct protector of business value. (If you are at the other end of the practice lifecycle, start with our guide on how to open a med spa — the entity and licensing choices made at launch determine how sellable the practice is later.)

---

Direct Answer: 2026 Med Spa Valuation Benchmarks

In a transaction, medical spas and aesthetic practices are valued strictly on a multiple of adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization), not gross revenue.

• Small / Single-Site Clinics (<$3M Revenue): 3.0x to 5.0x EBITDA.
• Mid-Sized / Multi-Location Groups ($3M–$15M Revenue): 5.0x to 8.0x EBITDA.
• Large Regional Platforms (>$15M Revenue): 8.0x to 12.0x+ EBITDA.
• Premium Membership-Led Networks: 10.0x to 13.0x+ EBITDA (due to the predictability of cash flow).
• Private Equity Penetration: Approximately 3% to 4% of the US med spa market is consolidated by the 30+ active PE-backed platforms (e.g., Advanced MedAesthetic Partners, Empower Aesthetics, SkinSpirit), leaving roughly 96% to 97% fragmented.
• Recent Transaction Markers: Advanced MedAesthetic Partners (backed by Leon Capital Group) acquired Ever/Body on December 19, 2025; in June 2026, Reuters reported that LaserAway (backed by its founders, Ares Management, and Seidler Equity Partners) had begun exploring a sale — with Harris Williams advising — that could value the chain at more than $2 billion.

---

Revenue vs. EBITDA: The Valuation Trap

The most common mistake made by med spa owners is assuming their practice is worth a multiple of its top-line revenue. It is common to hear owners claim, "My med spa is doing $2 million in revenue, so it must be worth $2 million." This is a valuation trap.

Buyers do not buy revenue; they buy cash flow—specifically, transferable Adjusted EBITDA. Top-line revenue tells a buyer how popular a clinic is, but it tells them nothing about whether the business can actually generate a profit once the owner departs.

To illustrate this, consider two hypothetical practices:

• Practice A (The Revenue Giant): Generates $2.5 million in gross revenue. However, it operates in a highly competitive market with high customer acquisition costs (CAC). To drive volume, it runs frequent discounts on injectables, resulting in a low margin of 3%. Furthermore, the founding physician personally performs 75% of the injections. The adjusted EBITDA is only $75,000.
• Practice B (The EBITDA Machine): Generates $1.5 million in gross revenue. It focuses on high-margin treatments (such as RF microneedling and skin therapeutics), runs a successful membership program, and has a staff of three nurse-injectors who handle 90% of the patient volume. The owner focuses on management, and the clinic maintains a healthy 25% margin. The adjusted EBITDA is $375,000.

In an M&A transaction, Practice B will be valued significantly higher than Practice A, despite having $1 million less in revenue. Practice B is a transferable business that can survive the owner's departure; Practice A is a job for the owner disguised as a business, carrying immense key-man risk.

┌────────────────────────────────────────────────────────┐
│             The EBITDA Normalization Process           │
├────────────────────────────────────────────────────────┤
│  Reported Net Income                                   │
│  [+] Add-backs: Interest, Taxes, Depreciation          │
│  [=] Standard EBITDA                                   │
│  [+] Owner Salary Adjustment (reduce to market rate)   │
│  [+] Personal Expenses (owner vehicles, travel, etc.)   │
│  [+] One-time Expenses (legal fees, office move)       │
│  [-] Rent Adjustment (if owner owns building at above- │
│      market rates)                                     │
│  [=] ADJUSTED EBITDA (The basis for transaction price) │
└────────────────────────────────────────────────────────┘

The Normalization Process (Adjusted EBITDA)

Before a med spa goes to market, its financial statements must undergo "normalization"—the process of adjusting the profit and loss (P&L) statement to reflect what the expenses would look like under a third-party buyer. Common adjustments include:

1. Replacement Compensation: If the owner is a doctor or nurse-injector who pays themselves a nominal salary (or draws money out of the business profit), the P&L must be adjusted to include the cost of hiring a replacement provider at fair market value (typically 15% to 20% of their personal production revenue).
2. Discretionary Personal Expenses: Any personal auto leases, family members on payroll who do not work, personal travel, and country club memberships run through the business must be added back to the profit.
3. One-Time Non-Recurring Expenses: Costs like a lawsuit settlement, a rebranding project, or an office move are added back to the EBITDA because they will not recur post-sale.

---

2026 Size-Tiered Valuation Multiples

Valuation multiples in the medical aesthetics space are highly sensitive to scale. The table below represents the current market multiples for aesthetic practices in 2026:

The Multiple Expansion Arbitrage

The reason large platforms command such high multiples is a financial strategy known as multiple expansion.

Private equity groups buy a large "platform" company at a high multiple (e.g., 10x EBITDA). They then purchase smaller, independent med spas ("add-ons") at lower multiples (e.g., 4x EBITDA). By integrating these add-ons into the platform—consolidating accounting, marketing, purchasing power, and management—the add-on's earnings are immediately valued at the platform's higher multiple.

For example, if a PE firm buys a small med spa with $500,000 of EBITDA for 4x ($2 million) and folds it into a platform that will eventually sell for 10x, they have instantly turned that $500,000 of EBITDA into $5 million of value—a $3 million arbitrage gain before any operational improvement is made.

---

Key Value Drivers: What Multiplies the Multiple

Two med spas with the exact same revenue and EBITDA can still receive wildly different multiples. The difference is determined by several qualitative value drivers:

1. Transferability (The Owner-Provider Problem)

The single biggest risk in valuing an aesthetic clinic is the degree of owner concentration.

• The Scenario: A physician owns a med spa. She is the lead injector, has a loyal patient base, and has built the clinic's reputation around her personal skill.
• The Problem: If she sells the business and retires, a significant portion of the patient base will follow her or seek another provider. The cash flow is not transferable.
• The Value Impact: A buyer will heavily discount this practice, often offering a 2.5x–3.0x multiple, and will require the owner to sign a strict 2-to-3-year transition employment contract, holding back a large portion of the purchase price in escrow.
• The Fix: Owners who want to sell at a premium must transition themselves out of the treatment room at least 18 to 24 months before a sale. They must hire and train associate injectors, build the brand around the clinic name rather than their personal name, and transition patient relationships to the staff.

2. Membership and Recurring Revenue

Sponsors love predictable cash flow. Med spas have historically suffered from seasonal fluctuations, with demand peaking in Q4 (before the holidays) and dipping in Q3 (summer).

• The Membership Solution: Implementing a structured membership program (e.g., monthly subscription fees that credit towards treatments, or flat-rate monthly fees for access to a set number of toxin units and facials). Program design, revenue-recognition, and compliance mechanics are covered in our guide to med spa membership programs, accounting, and compliance.
• The Value Impact: A med spa where 30% to 40% of revenue comes from recurring memberships commands a multiple premium of 0.5x to 1.0x over a clinic that relies entirely on transaction-by-transaction walk-ins. Memberships lock in customer lifetime value (LTV) and lower customer acquisition costs (CAC).

   [Toxin/Filler Focus Only]              [Membership/Skin Focus]
┌──────────────────────────────┐       ┌──────────────────────────────┐
│• Low repeat rate (3-4 months)│       │• Monthly recurring revenue   │
│• High price shopping         │       │• Higher service cross-sell   │
│• Low margin on brand drugs   │       │• High margin on device/skin  │
│• Multiple: 3.0x - 4.5x       │       │• Multiple: 5.5x - 7.5x       │
└──────────────────────────────┘       └──────────────────────────────┘

3. Provider Retention and Incentives

In aesthetics, the nurse-injectors and aesthetic physicians are the face of the business. If the lead injector leaves post-acquisition, the business can lose 50% of its value overnight.

• The Diligence Test: Buyers will review employment agreements, compensation structures (commission vs. base + bonus), and non-compete clauses (where legally enforceable).
• The Value Asset: A practice that has long-tenured injectors on structured retention agreements, or those who have been offered phantom stock or equity rollover incentives in the parent platform, is considered a lower-risk asset and commands a higher multiple.

---

Regulatory Diligence & CPOM Compliance

A major hurdle in med spa transactions is regulatory compliance. Because medical aesthetics involves medical procedures (including injections of prescription drugs like botulinum toxin and dermal fillers, and the use of Class II and III medical devices like lasers), it is subject to the Corporate Practice of Medicine (CPOM) doctrine in most states.

The CPOM Doctrine

Under the CPOM doctrine, non-physicians (including corporations, business managers, and private equity firms) are legally prohibited from owning medical practices or employing physicians and nurses to practice medicine. Only licensed physicians or physician-owned professional corporations (PCs) can own medical practices.

The PC-MSO Model

To acquire and operate med spas legally, private equity firms and non-physician buyers utilize the PC-MSO model:

┌─────────────────────────────────┐
│       PE / Non-Physician        │
│  Management Services Org (MSO)  │
└────────────────┬────────────────┘
                 │
                 │ Management Agreement (MSO Fee)
                 ▼
┌─────────────────────────────────┐
│      Licensed Physician         │
│   Professional Corp (PC)        │
├─────────────────────────────────┤
│• Owns medical records           │
│• Employs clinical staff         │
│• Holds medical licenses         │
└─────────────────────────────────┘

1. The Professional Corporation (PC): Owned 100% by a licensed physician (often a "friendly doctor" partner of the platform). The PC owns the clinical charts, employs the clinical staff (nurses, physicians), and is legally responsible for patient care.
2. The Management Services Organization (MSO): Owned by the PE firm or non-physician buyers. The MSO owns the real estate, leases the medical equipment, manages the marketing, handles billing and accounting, and provides all non-clinical administrative services.
3. The Management Services Agreement (MSA): The MSO charges the PC an administrative fee in exchange for these services. The fee must be set at fair market value — in many states, structuring it as a percentage of professional revenue or profits can violate state fee-splitting and kickback prohibitions. Done correctly, this fee transfers the economic value of the practice's non-clinical operations to the MSO legally. (The supervising-physician side of this structure is covered in our guides to finding a medical director for a med spa and what a compliant medical director agreement contains.)

Why Compliance Failures Kill Deals

During due diligence, a buyer's legal team will inspect the seller's corporate structure. If they find:

• A nurse practitioner or non-physician owning the clinic directly in a CPOM state without a PC-MSO structure.
• Inadequate physician supervision of nurse-injectors (a doctor who is "medical director" in name only and lives in another state, violating local medical board rules).
• Clinicians injecting off-label or importing unapproved cosmetic drugs (such as non-FDA cleared toxins).

The buyer will either walk away from the deal or require the seller to restructure the business prior to close, delaying the transaction for months and heavily discounting the purchase price to account for the regulatory risk.

---

Deal Structure in 2026 Transactions

Owners often expect that a sale means receiving 100% of the purchase price in cash at close. In modern M&A, particularly with private equity buyers, this is rarely the case. Deal structure is used to align the seller's incentives with the buyer's post-close growth.

A typical PE deal structure for a mid-sized med spa ($5 million value) consists of:

• 60% to 75% Cash at Close: The immediate liquidity event for the owner.
• 15% to 20% Rollover Equity: The seller is required to reinvest a portion of their proceeds into the equity of the buying platform. If the platform grows and undergoes a secondary sale (a "second bite of the apple"), this equity can multiply in value.
• 10% to 15% Earnout or Holdback: Funds held in escrow or paid out over 1 to 3 years, contingent on the practice hitting specific post-close EBITDA targets or the smooth transition of key staff.

The "Re-Trade" Playbook

A common issue for unrepresented sellers is the re-trade. During the initial phase, a buyer submits a Letter of Intent (LOI) with a high valuation. However, during the 60-to-90-day exclusive due diligence period, the buyer's accountants and lawyers dig into the P&L and operations.

If they find declining customer retention, poor charting, or regulatory non-compliance, they will "re-trade" the deal, lowering the purchase price right before closing when the seller has already invested significant time and legal fees and is emotionally committed to the sale.

Engaging an M&A advisor can prevent this. Statistics from sell-side broker databases (Aesthetic Brokers/HealthFMV) show that sellers represented by experienced M&A advisors achieve roughly 23% higher EBITDA multiples on average than unrepresented sellers, and they benefit from tighter LOI terms that prevent arbitrary re-trades.

---

Clinical Safety & Compliance as a Financial Asset

In aesthetic medicine, clinical safety is not just a regulatory obligation; it is a financial asset that directly impacts the valuation multiple. When a buyer evaluates a med spa, they assess the risk of post-close lawsuits, medical board investigations, and brand damage.

The Diligence Checklist for Safety

A practice that commands a premium multiple has:

1. Laser Safety Officer (LSO) Logbooks: Up-to-date logs detailing annual calibration, shot counts, and safety officer training for all light and energy-based devices.
2. Standardized Charting Protocols: Complete patient records documenting skin-type analysis (Fitzpatrick classification), medical history, drug contraindication reviews, consent forms, lot numbers, and injection maps.
3. Adverse Event Triage SOPs: Written Standard Operating Procedures (SOPs) for handling complications (e.g., immediate hyaluronidase protocols for vascular occlusions, post-laser burn management).
4. Device Legitimacy: 100% of devices purchased directly from the manufacturer or certified distributors, with active service contracts, ensuring no gray-market lasers or counterfeit injectables exist.

A clinic that cannot produce these documents is considered a high-risk liability, which will lead to a higher "indemnity escrow" (money held back by the buyer to cover future legal claims) and a lower overall valuation. Staffing compliance is scrutinized in the same pass — see our guide to employee vs independent contractor classification in med spas for the misclassification exposure buyers price in.

---

Key Due Diligence Metrics to Track

When a professional M&A advisory firm or private equity sponsor initiates due diligence, they will request access to your Electronic Medical Records (EMR) software (such as Zenoti, Mindbody, Boulevard, or Jane) to pull transaction and scheduling data. They look beyond the tax returns to verify the health of the patient base.

A clinic seeking a premium multiple should track and optimize the following metrics:

1. Retention Rate by Treatment Category

Sponsors calculate retention as the percentage of patients who return for a second treatment within 12 months.

• Neuromodulators (Botox/Dysport): Target retention is 65% to 75%. Because these drugs wear off in 3 to 4 months, a lower repeat rate suggests poor clinical outcomes, weak front-desk follow-up, or price-shopping behavior.
• Aesthetic Devices (Lasers/RF): Target retention is 45% to 55%. Because these are typically sold in packages (e.g., 3 sessions of RF microneedling), buyers inspect the "completion rate" of packages and the subsequent conversion to maintenance packages.
• Skin Therapeutics (Facials/Chemical Peels): Target retention is 50% to 60%. This is a key indicator of recurring monthly traffic that feeds the higher-ticket injectable services.

2. Customer Acquisition Cost (CAC) to Lifetime Value (LTV) Ratio

• Calculation: LTV is the total gross profit generated by a patient over their entire relationship with the clinic; CAC is the total marketing spend divided by the number of new patients acquired.
• Benchmark: Premium buyers require an LTV-to-CAC ratio of at least 3:1 to 5:1. A ratio below 3:1 indicates the clinic is overspending on ads (e.g., Google Ads or social media marketing) to buy unprofitable, single-visit discount shoppers.

3. Toxin-to-Filler-to-Device Revenue Mix

The mix of services determines the ultimate profit margin of the practice.

• The Toxin Trap: Botulinum toxin has a high repeat rate but low margins. Toxin drugs are expensive to buy — the drug alone typically consumes roughly 40% to 50% of the service price, as we quantify in our med spa consumable costs and unit economics breakdown. A med spa that derives 60% of its revenue from toxins will struggle to maintain an EBITDA margin above 15%.
• The Device Advantage: Energy-based devices (such as Ultherapy or Halo) carry high gross margins because there is no per-treatment drug cost (excluding minor consumable tips). Once the device capital expenditure is amortized, margins can exceed 80% — our device lease vs purchase ROI model shows how the financing choice moves that margin.
• The Ideal Mix: A premium clinic target mix is roughly 30% toxins (for high-frequency traffic), 30% dermal fillers/injectables, 30% energy-based devices (for high-margin volume), and 10% medical skincare sales/therapeutics.

4. Non-Compete Uncertainty and M&A Implications

In previous years, buyers relied on aggressive non-compete agreements to prevent key nurse-injectors from leaving post-close and opening a competing clinic down the street. That legal foundation has become unreliable. The Federal Trade Commission's 2024 rule that would have banned most employee non-competes nationwide never took effect — a federal court set it aside in August 2024 (Ryan LLC v. FTC), and the FTC formally abandoned its appeal in September 2025 — but the agency has continued case-by-case enforcement actions against specific employers' non-competes. Meanwhile, state-level legislation (such as California's complete ban on employee non-compete covenants, and narrower restrictions in a growing list of states) makes enforceability a state-by-state question.

• The Valuation Impact: Buyers now view provider departure as a higher risk, because they cannot assume a non-compete will hold.
• The M&A Shift: Rather than relying on legal bans (non-competes), buyers protect value through positive financial alignment. This includes structuring larger portions of the transaction as rollover equity in the parent company, introducing long-term incentive plans (LTIPs) such as phantom stock options for non-owner injectables providers, and structuring compensation models that reward retention and team production rather than individual commissions.

---

Frequently Asked Questions

How is Adjusted EBITDA calculated for a med spa?

Start with your net income from your tax return. Add back interest expense, income taxes paid, depreciation on equipment, and amortization of intangible assets. Then, adjust for owner compensation: if the owner works in the business, replace their actual pay with the market rate for their job. Add back personal expenses run through the business (vehicles, travel) and any one-time expenses (rebranding, legal disputes). The result is Adjusted EBITDA.

What is a "friendly PC" structure?

It is a professional medical corporation owned by a licensed physician who is aligned with the MSO's management. The physician signs a stock transfer agreement that allows the MSO to transition the ownership of the PC to another licensed physician in the future (e.g., if the original physician retires or dies), ensuring the MSO maintains long-term control of the business without violating the CPOM doctrine.

How long does it take to sell a medical spa?

A standard M&A transaction takes 6 to 9 months from the initial preparation phase to closing. The process involves preparing the financial book (CIM), marketing the business to buyers, receiving and negotiating Letters of Intent (LOIs), undergoing 60 to 90 days of due diligence, and drafting the final purchase and management agreements.

---

Sources

1. FOCUS Investment Banking Medspa Multiples Dashboard (2026 Update):
   Analysis of Private Equity Consolidation, EBITDA Multiples, and MSO Structures
   URL: https://focusbankers.com/medspa-valuation-multiples/
2. Greenwich Capital Group Industry Report (April 2025):
   Evaluating Aesthetics: MedSpa Growth and Strategic Consolidation
   URL: https://greenwichgp.com/wp-content/uploads/2025/04/Evaluating-Aesthetics-MedSpa-Growth-and-Strategic-Consolidation.pdf
3. American Med Spa Association (AmSpa):
   The Business, Legal and Financial Aspects of MSOs — Corporate Practice of Medicine and PC-MSO Regulatory Framework
   URL: https://www.americanmedspa.org/news/the-business-legal-and-financial-aspects-of-msos
4. Greenwich Capital / Viper Equity M&A Transaction Database:
   Transaction Volumes, Valuation Multiples, and Buyer Classifications in Aesthetics
   URL: https://www.viperequitypartners.com/viper-insights/private-practice-consolidation-2025-trends
5. Aesthetic Brokers sell-side analytics report:
   How Private Equity Buys Med Spas — Unrepresented Sellers, the 23% M&A Advisor Premium (HealthFMV benchmarking), and PE Penetration (3%–4%, 30+ platforms)
   URL: https://aestheticbrokers.com/blog/insights-about-private-equity-sales
6. Reuters (June 4, 2026):
   Ares-backed medical spa chain LaserAway explores sale that could value it at more than $2 billion, with Harris Williams advising
   URL: https://www.reuters.com/legal/transactional/ares-backed-medical-spa-chain-laseraway-explores-sale-sources-say-2026-06-04/